These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22326642)

  • 1. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
    Halperin SA; McNeil S; Langley JM; Smith B; MacKinnon-Cameron D; McCall-Sani R; Heyward WL; Martin JT
    Vaccine; 2012 Aug; 30(36):5445-8. PubMed ID: 22704926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
    Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
    Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
    Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
    Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
    Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
    Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
    Halperin SA; Van Nest G; Smith B; Abtahi S; Whiley H; Eiden JJ
    Vaccine; 2003 Jun; 21(19-20):2461-7. PubMed ID: 12744879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
    Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
    Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
    Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
    Cooper C; Mackie D
    Expert Rev Vaccines; 2011 Apr; 10(4):417-27. PubMed ID: 21506639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.
    Cooper CL; Angel JB; Seguin I; Davis HL; Cameron DW
    Clin Infect Dis; 2008 Apr; 46(8):1310-4. PubMed ID: 18444872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
    Janssen JM; Heyward WL; Martin JT; Janssen RS
    Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of HBV vaccine during stated shelf-life.
    Gloriani NG; Srinivasa K; Bock HL; Hoet B
    Southeast Asian J Trop Med Public Health; 2010 Jul; 41(4):876-82. PubMed ID: 21073062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
    Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
    Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.